Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISH 2022 | Mechanism of action & use of daratumumab in multiple myeloma

Maria-Victoria Mateos • 8 Oct 2022
ISH 2022
Multiple Myeloma Antibodies Bortezomib Carfilzomib Daratumumab Dexamethasone Lenalidomide Pomalidomide

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the mechanism of action of daratumumab in multiple myeloma, commenting on its use in the frontline and relapsed/refractory (R/R) settings in transplant-eligible and transplant-ineligible patients. This interview took place at the 38th World Congress of the International Society of Hematology (ISH) 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals